NCT06055374View on ClinicalTrials.gov

A Study to Investigate the Safety, Tolerability, and Efficacy of BxC-I17e Repeated-dose SC Injection in Patients With Moderate to Severe Atopic Dermatitis

PHASE1WithdrawnINTERVENTIONAL
0
Timeline

Start Date

May 1, 2024

Primary Completion Date

April 30, 2025

Study Completion Date

August 30, 2025

Conditions
Atopic Dermatitis
Interventions
DRUG

BxC-I17e

Pharmaceutical form : solution for injection

DRUG

Placebo

Pharmaceutical form : solution for injection

Sponsors

Lead Sponsor

Brexogen Inc.
All Listed Sponsors
lead

Brexogen Inc.

INDUSTRY